BofA lowered the firm’s price target on Conmed (CNMD) to $52 from $65 and keeps a Neutral rating on the shares after the company said it will exit its gastroenterology product lines. The exit is accretive to gross margins but dilutive to earnings in 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNMD:
- Conmed’s Strategic Exit from Gastroenterology: Hold Rating Amid Portfolio Optimization and Financial Adjustments
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Midday Fly By: Netflix to buy Warner Bros., HP Enterprise posts mixed Q4
- Conmed Exits Gastroenterology Products to Focus on Core Markets
- Conmed to conclude distribution agreement with W. L. Gore & Associates